**INTRODUCTION:** Impaired wound repair represents a major health risk and a substantial burden to healthcare systems worldwide. While the factors that may facilitate wound repair may be manifold, subcutaneous adipose tissue plays a central, yet underappreciated role as it is a dynamic organ situated in immediate proximity to the skin and participates in wound repair inter alia by the secretion of soluble factors. The macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that was earlier described in the context of chronic adipose tissue inflammation. D-dopachrome tautomerase (DDT, MIF-2) was only recently added to the MIF protein superfamily and although its exact functions are unknown, DDT is considered a functional homologue of MIF. The purpose of the present study was to investigate the expression of adipose tissue-derived MIF and DDT in wound healing disorders and elucidate their functions on dermal fibroblasts and cell mobilization.

**MATERIALS AND METHODS:** Subcutaneous adipose tissue samples were collected from wounds that showed delayed healing accompanied by classical signs of local inflammation. Subcutaneous tissue from healthy donor sites served as controls. Protein and mRNA expression were measured and their paracrine effect on the migration and proliferation of human dermal fibroblast was assessed in vitro. Finally, macrophage mobilization was evaluated by an in vivo cell tracking experiment.

**RESULTS:** Adipose tissue from wound healing disorders showed increased MIF expression whereas DDT was down-regulated. MIF is localized in adipocytes and infiltrated macrophages. DDT, by contrast, is primarily found in macrophages. While adipose tissue-derived MIF inhibited fibroblast proliferation, DDT supported fibroblast proliferation. Both family members recruited macrophages but the effect of MIF was more pronounced.

**CONCLUSIONS:** MIF and DDT show a hitherto unknown reciprocal role in adipose tissue adjacent to non-healing wounds, which may gain importance in therapeutic strategies (e.g. MIF antibodies / recombinant DDT) in the future.
